[HTML][HTML] Latent rheumatic, thyroid and phospholipid autoimmunity in hospitalized patients with COVID-19

JM Anaya, DM Monsalve, M Rojas, Y Rodríguez… - Journal of translational …, 2021 - Elsevier
JM Anaya, DM Monsalve, M Rojas, Y Rodríguez, N Montoya-García, LM Mancera-Navarro…
Journal of translational autoimmunity, 2021Elsevier
Autoimmune responses mediated by autoantibodies have been observed in SARS-CoV-2
infection. Herein, we evaluate the presence of rheumatic, thyroid and phospholipid
autoantibodies in sera samples from 120 adult hospitalized patients with COVID-19 in
comparison to pre-pandemic samples from 100 healthy individuals. In addition, to estimate
the frequency of these autoantibodies in COVID-19, a meta-analysis of selected articles was
conducted. Hospitalized patients with COVID-19 had latent autoimmunity characterized by a …
Abstract
Autoimmune responses mediated by autoantibodies have been observed in SARS-CoV-2 infection. Herein, we evaluate the presence of rheumatic, thyroid and phospholipid autoantibodies in sera samples from 120 adult hospitalized patients with COVID-19 in comparison to pre-pandemic samples from 100 healthy individuals. In addition, to estimate the frequency of these autoantibodies in COVID-19, a meta-analysis of selected articles was conducted. Hospitalized patients with COVID-19 had latent autoimmunity characterized by a high frequency of anti-thyroid peroxidase antibodies, rheumatoid factor (RF), anti-cyclic citrullinated peptide third generation antibodies, antinuclear antibodies (ANAs), IgM anti-β2-glycoprotein I (β2GP1) and IgM anti-cardiolipin antibodies. The meta-analysis confirmed our results, with RF and ANAs being the most common autoantibodies. In addition, cluster analysis revealed that those patients with high frequency of RF, IgM anti-β2GP1 antibodies and ANAs had a longer hospital stay, required more vasopressors during hospitalization, and were more likely to develop critical disease. These data suggest that latent autoimmunity influences the severity of COVID-19, and support further post-COVID studies in order to evaluate the development of overt autoimmunity.
Elsevier
以上显示的是最相近的搜索结果。 查看全部搜索结果